# A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia

> **NCT00482703** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 23 (actual)

## Conditions studied

- Myeloid Leukemia, Chronic

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** dasatinib

## Key facts

- **NCT ID:** NCT00482703
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2010-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00482703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00482703, "A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00482703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*